Medindia

X

FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks

Tuesday, August 30, 2016 Men´s Health News J E 4
Advertisement

KING OF PRUSSIA, Pa., Aug. 30, 2016 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks.  HAE is a rare genetic disorder caused by a deficiency of C1-INH, one of the proteins that work with the body's immune system to control inflammation.  Symptoms of HAE include episodes of swelling in the face, abdomen, larynx and extremities and can be fatal if untreated. 

"The review of this application is another step towards providing advanced prophylactic treatment options to people living with HAE," said Dr. Andrew Cuthbertson, Chief Scientific Officer and R&D Director, CSL Limited.  "Since CSL Behring first reported the possibility of C1-INH replacement therapy for HAE over 40 years ago, we have remained committed to innovative research and providing advanced treatment options to people living with HAE.  Subcutaneous prophylaxis is the next important step in helping HAE patients to prevent HAE attacks."

About Hereditary Angioedema HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people.   HAE is caused by lack of or malfunctioning C1-INH. As a result, there are inadequate amounts of properly functioning C1-INH, leading fluid to build up in body tissues, causing considerable swelling episodes referred to as angioedema.  HAE attacks can affect many parts of the body and can spread to multiple sites, including the face, abdomen, larynx and extremities. Patients who have abdominal attacks of HAE can experience episodes of extreme pain, diarrhea, nausea and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if untreated, death.

About Subcutaneous C1 Esterase Inhibitor (C1-INH)C1 Esterase Inhibitor (Human) is an investigational, low-volume, subcutaneous prophylactic therapy.  C1-INH replaces the missing or malfunctioning C1-INH protein in patients with a C1-INH deficiency, thereby preventing HAE attacks.

About CSL BehringCSL Behring is a global biotherapeutics leader which is driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 16,000 people with operations in more than 30 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fda-accepts-csl-behrings-biologics-license-application-for-first-subcutaneous-prophylactic-therapy-to-prevent-hereditary-angioedema-attacks-300319903.html

SOURCE CSL Behring

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Fluoridation Useless for Low-Income Children, Fede...
S
American Sentinel University Presents Donation to ...